PT2619576T - Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro - Google Patents

Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro

Info

Publication number
PT2619576T
PT2619576T PT117733816T PT11773381T PT2619576T PT 2619576 T PT2619576 T PT 2619576T PT 117733816 T PT117733816 T PT 117733816T PT 11773381 T PT11773381 T PT 11773381T PT 2619576 T PT2619576 T PT 2619576T
Authority
PT
Portugal
Prior art keywords
prediction
methods
cancer patient
treatment response
response
Prior art date
Application number
PT117733816T
Other languages
English (en)
Original Assignee
Niels Grabe
Niels Halama Dr
Dirk Jaeger
Inka Zoernig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44862915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2619576(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Niels Grabe, Niels Halama Dr, Dirk Jaeger, Inka Zoernig filed Critical Niels Grabe
Publication of PT2619576T publication Critical patent/PT2619576T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96436—Granzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
PT117733816T 2010-09-24 2011-09-20 Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro PT2619576T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10010537 2010-09-24

Publications (1)

Publication Number Publication Date
PT2619576T true PT2619576T (pt) 2020-09-14

Family

ID=44862915

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117733816T PT2619576T (pt) 2010-09-24 2011-09-20 Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro

Country Status (10)

Country Link
US (1) US9726676B2 (pt)
EP (1) EP2619576B1 (pt)
DK (1) DK2619576T3 (pt)
ES (1) ES2816625T3 (pt)
HR (1) HRP20201424T1 (pt)
HU (1) HUE051674T2 (pt)
PL (1) PL2619576T3 (pt)
PT (1) PT2619576T (pt)
SI (1) SI2619576T1 (pt)
WO (1) WO2012038068A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
US20120171694A1 (en) * 2010-07-30 2012-07-05 Vermillion, Inc. Predictive markers and biomarker panels for ovarian cancer
RU2626540C2 (ru) 2011-04-18 2017-07-28 Диамир, Ллс Способы обнаружения патологических изменений в органе или системе органов
US9760760B2 (en) * 2012-01-19 2017-09-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histology recognition to automatically score and quantify cancer grades and individual user digital whole histological imaging device
US20130203614A1 (en) * 2012-02-08 2013-08-08 Jerome Galon Methods for predicting the survival time of a patient suffering from a solid cancer
AU2013240224A1 (en) * 2012-03-30 2014-10-16 Sloan-Kettering Institute For Cancer Research S100A8/A9 as a diagnostic marker and a therapeutic target
US20150218650A1 (en) * 2012-08-06 2015-08-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and kits for screening patients with a cancer
DK2888591T3 (da) * 2012-08-21 2019-01-02 Medetect Ab Fremgangsmåde til forbedret celleidentifikation
WO2014039654A1 (en) * 2012-09-06 2014-03-13 Joslin Diabetes Center, Inc. Isolation and characterization of muscle regenerating cells
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
WO2014173860A1 (en) * 2013-04-23 2014-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a combination of iron uptake inhibitor and vitamin d receptor agonist
WO2015073972A1 (en) 2013-11-18 2015-05-21 Diamir, Llc METHODS OF USING mIRNAs FROM BODILY FLUIDS FOR DETECTION AND MONITORING OF PARKINSON'S DISEASE (PD)
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
ES2701092T5 (es) * 2014-02-24 2022-05-12 Ventana Med Syst Inc Procedimientos, kits y sistemas para puntuar la respuesta inmunitaria al cáncer por detección simultánea de CD3, CD8, CD20 y FOXP3
EP3215852A4 (en) * 2014-11-05 2018-04-04 The Regents of the University of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
KR101751929B1 (ko) * 2015-01-05 2017-06-28 서울대학교 산학협력단 신규 간암 환자의 소라페닙 저항성 예측 마커
US20160258848A1 (en) * 2015-03-04 2016-09-08 Agilent Technologies, Inc. Methods and compositions for multiplex tissue section analyses using visible and non-visible labels
EP3839510A3 (en) * 2015-04-17 2021-08-25 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
US10839509B2 (en) 2015-07-10 2020-11-17 3Scan Inc. Spatial multiplexing of histological stains
EP3341732B1 (en) * 2015-08-27 2023-07-12 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the survival time of patients suffering from a lung cancer
AU2016341306B2 (en) * 2015-10-23 2022-10-27 Novartis Ag Computer processes behind an enhanced version of aqua
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
WO2017165458A1 (en) 2016-03-21 2017-09-28 Diamir, Llc Methods of using mirnas from bodily fluids for detection and differentiation of neurodegenerative diseases
WO2017189526A1 (en) * 2016-04-25 2017-11-02 Musc Foundation For Research Development Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
CN106084114B (zh) * 2016-06-08 2017-11-10 渤海大学 一种恩诺沙星适配体/分子印迹杂化型上转换荧光探针的制备方法
US9990713B2 (en) * 2016-06-09 2018-06-05 Definiens Ag Detecting and visualizing correlations between measured correlation values and correlation reference values of a pathway
EP3500290A4 (en) * 2016-08-19 2020-04-29 Brooklyn Immunotherapeutics LLC USES OF PD-1 / PD-L1 INHIBITORS AND / OR CTLA-4 INHIBITORS WITH A BIOLOGICAL CONTAINING MULTIPLE CYTOKINE COMPONENTS TO TREAT CANCER
EP3515495A4 (en) * 2016-09-26 2020-08-26 Ensemble Group Holdings METHOD OF EVALUATION AND TREATMENT OF CANCER IN HUMANS WITH DYSREGULATED LYMPHATIC SYSTEMS
WO2018102567A1 (en) * 2016-12-01 2018-06-07 Yale University Prediction of response to immune-modulatory therapies
US20200147210A1 (en) * 2017-05-11 2020-05-14 The General Hospital Corporation Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
US20180357361A1 (en) * 2017-06-13 2018-12-13 Feliks Frenkel Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
EP3649250A4 (en) * 2017-07-05 2021-03-24 The Regents of the University of California ASSAY FOR PREOPERATIVE PREDICTION OF RESTORATION OF ORGAN FUNCTION
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
US10950424B2 (en) * 2017-09-25 2021-03-16 Bruker Daltonik, Gmbh Method for monitoring the quality of mass spectrometric imaging preparation workflows
US20210341483A1 (en) * 2017-11-30 2021-11-04 Singapore Health Services Pte. Ltd. System and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient
EP3887548A1 (en) * 2018-11-30 2021-10-06 GBG Forschungs GmbH Method for predicting the response to cancer immunotherapy in cancer patients
CN109655624A (zh) * 2019-02-11 2019-04-19 臻和（北京）科技有限公司 一种用于预测癌症免疫治疗效果的标志物及其应用、试剂盒和试剂盒的制备方法
WO2020245155A1 (en) * 2019-06-03 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating a treatment regimen
CN110895280B (zh) * 2019-12-03 2022-11-18 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于预测鼻咽癌转移的免疫评分及其应用
WO2021156360A1 (en) * 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
CN115398556A (zh) * 2020-02-07 2022-11-25 赛诺菲 用于预测患者反应的系统和方法
US20210277345A1 (en) * 2020-03-06 2021-09-09 Tomoyuki Aratani Cell-containing container, method for evaluating test substance, and method for manufacturing cell-containing container
EP4321625A1 (en) * 2021-04-06 2024-02-14 Industry Foundation of Chonnam National University Method for predicting prognosis and responsiveness to anticancer therapy of cancer patients
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统
CN114622023A (zh) * 2021-09-09 2022-06-14 四川省肿瘤医院 一种预测肿瘤化疗联合免疫治疗疗效的标志物及其应用
CN114019163B (zh) * 2021-11-02 2024-07-23 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6711283B1 (en) * 2000-05-03 2004-03-23 Aperio Technologies, Inc. Fully automatic rapid microscope slide scanner
EP1428169B1 (en) * 2002-02-22 2017-01-18 Olympus America Inc. Focusable virtual microscopy apparatus and method
WO2005100606A2 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
GB0601509D0 (en) * 2006-01-26 2006-03-08 Maddison John Method And Apparatus For Aligning Microscope Images

Also Published As

Publication number Publication date
WO2012038068A3 (en) 2012-05-31
US9726676B2 (en) 2017-08-08
DK2619576T3 (da) 2020-09-07
WO2012038068A8 (en) 2013-11-28
HUE051674T2 (hu) 2021-03-29
US20130330325A1 (en) 2013-12-12
WO2012038068A2 (en) 2012-03-29
SI2619576T1 (sl) 2021-03-31
PL2619576T3 (pl) 2021-07-05
ES2816625T3 (es) 2021-04-05
EP2619576B1 (en) 2020-06-10
HRP20201424T1 (hr) 2021-02-19
EP2619576A2 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
PL2619576T3 (pl) Środki i sposoby do prognozowania odpowiedzi na leczenie u pacjenta chorego na nowotwór złośliwy
IL261768B (en) Devices and methods for tissue treatment
ZA201209484B (en) Skin antiaging treatment
EP2629736A4 (en) FABRIC TREATMENT
EP2611496A4 (en) Methods of Treatment
EP2627331A4 (en) METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
ZA201301601B (en) Treatment of diseases
SG10201508495VA (en) Combination treatment of cancer
EP2613786A4 (en) TREATMENT OF DISEASES
EP2606349A4 (en) AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY
ZA201300218B (en) Treatment of blood cancer
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
IL222958A0 (en) Cancer treatment
ZA201300762B (en) Novel combination therapy for the treatment of cancer
IL256026B (en) Treatment methods
EP2544686A4 (en) COMBINED METHODS FOR THE TREATMENT OF DISEASES
EP2635121A4 (en) ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER
IL275636A (en) Medical combination for cancer treatment
EP2593111A4 (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
EP2556161A4 (en) METHODS OF TREATING AUTOIMMUNE DISEASES
GB201016864D0 (en) Therapeutic methods
SI2566579T1 (sl) Medicinska naprava za magnetoterapijo
GB201113140D0 (en) Prediction and treatment of cancer
IL204097A0 (en) Medicine for the treatment of skin cancer
GB2477546B (en) Skin treatment apparatus